Cytophage Technologies (TSXV:CYTO.H) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Cytophage Technologies EBITDA Margin %?

Cytophage Technologies TSXV:CYTO.H EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Cytophage Technologies ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cytophage Technologies's EBITDA for the three months ended in Dec. 2025 was C$-0.63 Mil. Cytophage Technologies's Revenue for the three months ended in Dec. 2025 was C$0.00 Mil. Therefore, Cytophage Technologies's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Cytophage Technologies  (TSXV:CYTO.H) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cytophage Technologies EBITDA Margin % Related Terms

Cytophage Technologies EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies EBITDA Margin % Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSXV:CYTO.H vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Cytophage Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's EBITDA Margin % falls into.


Cytophage Technologies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cytophage Technologies's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.36/0
= %

Cytophage Technologies's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.625/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Cytophage Technologies (TSXV:CYTO.H) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cytophage Technologies and its competitors. According to the industry distribution chart, Cytophage Technologies ranks #999999 out of 945 companies in the Biotechnology industry.
Is Cytophage Technologies' EBITDA Margin % too high?
Cytophage Technologies' current EBITDA Margin % is 0.00%. Based on the distribution chart, Cytophage Technologies ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Cytophage Technologies' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cytophage Technologies ranks #999999 out of 945 companies for EBITDA Margin %. This places Cytophage Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cytophage Technologies and its competitors. Cytophage Technologies's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (TSXV:CYTO.H) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cytophage Technologies (TSXV:CYTO.H), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.